23:09 , May 17, 2019 |  BC Extra  |  Politics & Policy

Friends, Parker Institute call for more flexibility in early T cell therapy development

Friends of Cancer Research and the Parker Institute for Cancer Immunotherapy recommend more flexible IND and manufacturing requirements and the use of adaptive clinical trials to advance development of emerging cellular therapeutics such as CAR...
09:59 , May 7, 2019 |  BC Innovations  |  Emerging Company Profile

Verve turns CRISPR against cardiovascular disease

Most CRISPR companies are targeting rare genetic disorders, but Verve is breaking from the trend with gene editing therapies for coronary artery disease that could have fewer side effects, greater efficacy and better compliance than...
23:11 , Apr 25, 2019 |  BC Extra  |  Politics & Policy

RAC reborn as NExTRAC to advise NIH on safety, ethics of emerging technologies

After decades of waxing and waning authority over recombinant DNA and gene therapies, NIH's 45-year-old Recombinant DNA Advisory Committee is ending its reviews of individual clinical protocols and turning toward broader evaluation of newer technologies...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
17:40 , Apr 25, 2019 |  BC Innovations  |  Translation in Brief

Risking CRISPR correction before birth

A team from CHOP and UPenn has published its second study showing CRISPR-based gene editing can treat deadly diseases in the womb but has yet to address the safety repercussions for the mother and fetus....
17:24 , Apr 19, 2019 |  BC Week In Review  |  Company News

Ophthotech rebrands as Iveric as focus turns to retinal gene therapies

Ophthotech Corp. (NASDAQ:OPHT) changed its name and ticker to Iveric bio Inc. (NASDAQ:ISEE) as part of its shift to focus on gene therapies to treat orphan inherited retinal diseases. Last week, the company exercised its...
19:26 , Apr 15, 2019 |  BC Innovations  |  Distillery Therapeutics

miR-302 mimics for bacterial pneumonia

DISEASE CATEGORY: Infectious disease INDICATION: Pneumonia Mouse studies suggest miR-302 mimics could help treat pneumonia caused by Streptococcus pneumonia e. In a mouse model of pneumonia caused by S. pneumoniae , two miR-302 mimics decreased...
20:25 , Apr 5, 2019 |  BC Week In Review  |  Clinical News

Clovis' PARP inhibitor leads to PFS of 9.1 months in pancreatic cancer

Clovis reported at AACR that first-line maintenance treatment with Rubraca rucaparib led to a median progression-free survival of 9.1 months from the start of Rubraca therapy among 19 evaluable pancreatic cancer patients in an interim...
14:35 , Apr 1, 2019 |  BC Extra  |  Clinical News

MSKCC CAR T shows 72% response in mesothelioma

Researchers from MSKCC presented data for a mesothelin-targeted autologous CAR T cell therapy that could be the first to crack the solid tumor juggernaut for this treatment modality while also minimizing toxicity. The data could...
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...